Fixed-dose-combinations of Olmesartan/Amlodipine and Valsartan/Amlodipine for Treatment of Essential Hypertension: A Network Meta-analysis

OBJECTIVE To analyze and evaluate of the effect of olmesartan/amlodipine and valsartan/amlodipine fixed-dose combination in the treatment of essential hypertension patients by network meta-analysis. METHODS PubMed, Wanfang, CNKI were searched to retrieve results from reported randomized controlled trials in literature. Upon assessing the quality of publications in accordance to the Cochrane Handbook, conducted the network meta-analysis and indirect treatment comparison using the R3.4.3 and ITC software. RESULTS The final meta-analysis included a total of 9 studies and 3 137 patients. The olmesartan/amlodipine fixed-dose combination was statistically superior to valsartan/amlodipine fixed-dose combination in reducing systolic blood pressureMD=3.2 mmHg, 95%CI(0.548, 5.852), P=0.043. There was no difference for lowering diastolic blood pressure between the two treatmentsMD=0.1 mmHg, 95%CI(-1.847, 2.047), P=0.919. There was no difference for blood pressure control rate and adverse effects rate between the two treatments. CONCLUSION Olmesartan/amlodipine fixed-dose combination has superior systolic blood pressure lowering effect compared with valsartan/amlodipine fixed-dose combination but the two treatments are comparable for lowering diastolic blood pressure.